Skip to content
OpenCapital
Get started

Castle Biosciences CSTL Long-term receivables, net

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S2×+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetNoncurrent.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's long-term receivables, net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's long-term receivables, net?
Castle Biosciences (CSTL) reported long-term receivables, net of $1.92M in Q1 2026.
How has Castle Biosciences's long-term receivables, net changed year-over-year?
Castle Biosciences's long-term receivables, net increased by 92.1% year-over-year, from $1M to $1.92M.
What is the long-term trend for Castle Biosciences's long-term receivables, net?
Over 5 years (2020 to 2025), Castle Biosciences's long-term receivables, net has grown at a 11.4% compound annual growth rate (CAGR), from $1.1M to $1.88M.
What does long-term receivables, net mean?
This represents amounts owed to the company that are not expected to be collected within the next twelve months, net of any allowances for doubtful accounts. In the utility sector, this may include long-term financing arrangements or regulatory assets. It reflects the company's exposure to credit risk over an extended time horizon.